The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1303
January 12, 2009
View Complete Issue         Table of Contents 2019 
Silodosin (Rapaflo) for Benign Prostatic Hyperplasia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Silodosin (Rapaflo) for Benign Prostatic Hyperplasia
January 12, 2009 (Issue: 1303)
Silodosin (Rapaflo - Watson Pharmaceuticals), an alpha1a-adrenoreceptor selective antagonist, has been approved by the FDA for treatment of benign prostatic hyperplasia (BPH). Some medications for BPH are listed in the table on page 4. Alpha1...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Silodosin (Rapaflo) for Benign Prostatic Hyperplasia
Article code: 1303c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.